Monte Rosa Therapeutics, Inc. (GLUE), a clinical-stage biotechnology company, is scheduled to highlight interim clinical results from the ongoing Phase 1 study of MRT-8102, being developed for the treatment of inflammatory diseases, on January 7, 2026.
The presentation will include interim data from the ongoing Part 3 C-reactive protein (CRP) proof-of-concept cohort in participants with elevated cardiovascular disease risk.
The company will host a live conference call and webcast on Wednesday, January 7, 2026, at 8:00 a.m. ET to reveal the results.
Following the announcement, GLUE surged 8.62% at $17.39 in the after-hours market.
MRT-8102 is an experimental pill designed to break down a protein called NEK7. This helps treat inflammatory diseases caused by problems with certain immune signals like NLRP3, IL-1ß, and IL-6.
The Phase 1 study of MRT-8102 has three parts.
Part 1: Healthy volunteers receive a single oral dose of MRT-8102 or a placebo on Day 1.Part 2: Healthy volunteers receive multiple oral doses of MRT-8102 or a placebo daily for 7 days.Part 3: Participants with cardiovascular risk and high CRP receive multiple oral doses of MRT-8102 or a placebo daily for 28 days. (Source: Clinicalrials.gov).
As part of initiating the Phase 1 study, Monte Rosa planned to establish initial proof of concept for cardio-immunology indications by evaluating changes in C-reactive protein (CRP) and other key inflammatory markers in a cohort of subjects with elevated CRP levels.
The ongoing Phase 1 study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of MRT-8102 in healthy participants and in participants at cardiovascular risk with elevated CRP. The purpose of the study also includes the safety and tolerability of 28-day daily dosing of MRT-8102.
Monte Rosa's proprietary QuEEN discovery platform combines AI-driven chemistry, structural biology, and proteomics to enable the rational design of molecular glue degraders with selectivity. This technology supports a pipeline of Monte Rosa's MGDs, including three candidates currently in clinical development.
GLUE closed Tuesday's trade at $16.01, up 11.18%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.